<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03329274</url>
  </required_header>
  <id_info>
    <org_study_id>17-516</org_study_id>
    <nct_id>NCT03329274</nct_id>
  </id_info>
  <brief_title>Registry for Patients With Erdheim-Chester Disease</brief_title>
  <official_title>Registry for Patients With Erdheim-Chester Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators want to understand more about what kinds of health problems are caused by&#xD;
      Erdheim-Chester Disease (ECD), what happens as a result of different treatments for ECD, and&#xD;
      how ECD affects people's lives, their feelings and their attitudes. The investigators also&#xD;
      want to learn how these things change over time for people with ECD. To try to figure this&#xD;
      out, doctors would like to collect information about people who have ECD and how they are&#xD;
      treated for this disease.&#xD;
&#xD;
      Some participants will be asked to complete a brief interview over the telephone. Only a&#xD;
      limited number of interviews will take place, and not everyone will be asked to participate&#xD;
      in the interview. It is okay if the participant does not want to participate in the interview&#xD;
      portion. If this is the case, the participant should let the study team member know when&#xD;
      contacted.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 26, 2017</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Create registry for Erdheim-Chester Disease</measure>
    <time_frame>3 years</time_frame>
    <description>This ECD registry is motivated to capture comprehensive clinical information as well as patient-centered data about ECD patients.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Erdheim-Chester Disease</condition>
  <arm_group>
    <arm_group_label>Patients with Erdheim-Chester Disease</arm_group_label>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      tissue&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Erdheim-Chester Disease will be enrolled in this registry study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Erdheim-Chester Disease by either 1) documented histopathologic&#xD;
             establishing ECD or 2) documented histopathologic findings compatible with&#xD;
             Erdheim-Chester disease in the context of corroborating clinical and/or radiologic&#xD;
             findings or 3) documented radiologic findings, in the absence of a biopsy having been&#xD;
             performed or yielding evaluable tissue, that are felt by the Principal Investigator to&#xD;
             unequivocally represent an ECD diagnosis given the clinical context or 4) self&#xD;
             reported with supporting documentation upon medical record collection.&#xD;
&#xD;
          -  Proficiency in English, in the determination of the Investigator or by self report.&#xD;
&#xD;
          -  Willing to have historical and future ECD-related health records sent to Registry&#xD;
             review.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients unwilling to sign consent.&#xD;
&#xD;
          -  Participants under the age of 18.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eli Diamond, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eli Diamond, MD</last_name>
    <phone>212-610-0243</phone>
    <email>diamone1@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Katherine Panageas, PhD</last_name>
    <phone>646-888-8237</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Diamond, PhD</last_name>
      <phone>212-610-0243</phone>
    </contact>
    <contact_backup>
      <last_name>Katherine Panageas, MD</last_name>
      <phone>646-888-8237</phone>
    </contact_backup>
    <investigator>
      <last_name>Eli Diamond, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 26, 2017</study_first_submitted>
  <study_first_submitted_qc>October 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2017</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>registry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erdheim-Chester Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

